5,342 results match your criteria: "Monash Medical Centre.[Affiliation]"
BMC Anesthesiol
November 2024
Intensive Care Research, Austin Hospital and Co-director, Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), Melbourne, Australia.
Nutr Clin Pract
October 2024
Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Am J Obstet Gynecol MFM
October 2024
Department of Obstetrics & Gynecology, Monash University, Monash Medical Centre, Clayton, Victoria, Australia (Patabendige, Rolnik, Li, and Mol); Women's and Newborn, Monash Health, Victoria, Australia (Patabendige, Rolnik, and Mol).
Lancet Reg Health Eur
September 2024
Department of Orthopedic Surgery, Nemours Children's Health Delaware, Wilmington, USA.
Transplant Direct
November 2024
Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Background: Recurrent glomerulonephritis (GN) is an important cause of allograft loss after transplantation when GN is the primary cause of kidney failure. Retransplantation after allograft loss from recurrent disease requires careful consideration. We aimed to determine the probability of relisting and the risk of allograft loss after retransplantation in recipients with prior allograft loss from recurrent GN.
View Article and Find Full Text PDFInt J Biol Sci
October 2024
Departments of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, and Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Fibrosis is characterized by the aberrant deposition of extracellular matrix (ECM) due to dysregulated tissue repair responses, imposing a significant global burden on fibrosis-related diseases. Although alpha-smooth muscle actin (α-SMA/)-expressing myofibroblasts are considered as key player in fibrogenesis, the origin of ECM-producing cells remains controversial. To address this issue, we integrated and analyzed large-scale single-cell transcriptomic datasets from patients with distinct fibrotic diseases involving the heart, lung, liver, or kidney.
View Article and Find Full Text PDFEmerg Med Australas
February 2025
Monash Emergency Research Collaborative, Clinical Sciences at Monash Health, Clayton, Victoria, Australia.
Aim: To describe sources of advice and the recommendations given to parents/guardians prior to attending ED with their child.
Methods: This was a prospective observational study of patients presenting to two EDs of a multi-centre Victorian Health service in June 2016. Data collection involved surveying all parents/guardians attending paediatric ED during a 1-week period by trained research assistants.
Ann Rheum Dis
October 2024
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Introduction: Evidence from randomised controlled trials on anti-tumour necrosis factor (TNF) agents in patients with Behçet's syndrome (BS) is low.
Method: We conducted a phase 3, multicentre, prospective, randomised, active-controlled, parallel-group study to evaluate the efficacy and safety of either infliximab (IFX) or adalimumab (ADA) in patients with BS. Adults patients with BS presenting with active mucocutaneous manifestations, occurring while on therapy with either azathioprine or cyclosporine for at least 3 months prior to study entry, were eligible.
J Bone Miner Res
November 2024
Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, United Kingdom.
J Int Neuropsychol Soc
October 2024
Department of Psychology, Counselling & Therapy, School of Psychology & Public Health, La Trobe University, Melbourne, Australia.
Objectives: Cognitive impairment, anxiety, depression, fatigue, and dependence in instrumental activities of daily living (ADL) are common after stroke; however, little is known about how these outcomes may differ following treatment with endovascular clot retrieval (ECR), intravenous tissue plasminogen activator (t-PA), or conservative management.
Methods: Patients were recruited after acute treatment and invited to participate in an outcome assessment 90-120 days post-stroke. The assessment included a cognitive test battery and several questionnaires.
Am J Obstet Gynecol MFM
December 2024
Department of Obstetrics and Gynaecology, Monash University, Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre, 246 Clayton Rd, Clayton, Victoria 3168 Australia (Seo, Davies-Tuck, Warty, Smith, and Palmer); Monash Women's, Monash Health, 246 Clayton Rd, Clayton, Victoria Australia (Palmer).
Int J Immunopathol Pharmacol
October 2024
Department of Pediatrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Clin Endocrinol (Oxf)
January 2025
Department of Radiology, Alfred Hospital, Melbourne, Victoria, Australia.
Front Med (Lausanne)
September 2024
Rheumatology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Nephrology (Carlton)
December 2024
Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Australia.
Trop Med Infect Dis
September 2024
Sydney Infectious Diseases Institute, University of Sydney, Sydney, NSW 2050, Australia.
Tuberculosis, caused by the () bacteria, is one of the world's deadliest infectious diseases. Despite being the world's oldest pandemic, tuberculosis is very much a challenge of the modern era. In high-incidence settings, all people are at risk, irrespective of whether they have common vulnerabilities to the disease warranting the current WHO recommendations for community-wide tuberculosis active case finding in these settings.
View Article and Find Full Text PDF